Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

BioNTech SE - ADRTrade
iShares 20 Plus Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.07. The key difference: BioNTech SE - ADR is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

BNTXTLT
Market Cap
$23.31B
Sector
Health
52-Week High
$119.34$92.06
52-Week Low
$83.89$82.05
Enterprise Value
$6.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.

The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.

iShares 20 Plus Year Treasury Bond ETF

TLT (iShares 20+ Year Treasury Bond ETF) trades at $82.11, showing minimal daily movement with a 0.08% gain. The technical outlook remains bearish with moving averages signaling strong selling pressure, while oscillators indicate neutral momentum. Recent news highlights pressure from rising Treasury yields and concerns about US debt levels approaching $40 trillion, with institutional activity showing Ferguson Shapiro LLC acquiring 37,900 shares in the latest quarter.

The ETF faces headwinds from rising long-term yields and inflation concerns, though recent dividend payments provide income support. Key risks include Federal Reserve policy uncertainty and escalating geopolitical tensions affecting bond markets. Investors should monitor inflation data and Treasury yield movements for directional cues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About iShares 20 Plus Year Treasury Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.

Read more on TLT